Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Nov 11;321(7270):1190-5.
doi: 10.1136/bmj.321.7270.1190.

Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis

H Jick  1 , J A Kaye, C Vasilakis-Scaramozza, S S Jick
Affiliations

Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis

H Jick et al. BMJ. .

Abstract

Objective: To compare the risk of idiopathic venous thromboembolism among women taking third generation oral contraceptives (with gestodene or desogestrel) with that among women taking oral contraceptives with levonorgestrel.

Design: Cohort and case-control analyses derived from the General Practice Research Database.

Setting: UK general practices, January 1993 to December 1999.

Participants: Women aged 15-39 taking third generation oral contraceptives or oral contraceptives with levonorgestrel.

Main outcome measures: Relative incidence (cohort study) and odds ratios (case-control study) as measures of the relative risk of venous thromboembolism.

Results: The adjusted estimates of relative risk for venous thromboembolism associated with third generation oral contraceptives compared with oral contraceptives with levonorgestrel was 1.9 (95% confidence interval 1.3 to 2.8) in the cohort analysis and 2.3 (1.3 to 3.9) in the case-control study. The estimates for the two types of oral contraceptives were similar before and after the warning issued by the Committee on Safety of Medicines in October 1995. A shift away from the use of third generation oral contraceptives after the scare was more pronounced among younger women (who have a lower risk of venous thromboembolism) than among older women. Fewer cases of venous thromboembolism occurred in 1996 and later than would have been expected if the use of oral contraceptives had remained unchanged.

Conclusions: These findings are consistent with previously reported studies, which found that compared with oral contraceptives with levonorgestrel, third generation oral contraceptives are associated with around twice the risk of venous thromboembolism.

PubMed Disclaimer

Comment in

  • Pitfalls of pharmacoepidemiology.
    Skegg DC. Skegg DC. BMJ. 2000 Nov 11;321(7270):1171-2. doi: 10.1136/bmj.321.7270.1171. BMJ. 2000. PMID: 11073496 Free PMC article. No abstract available.
  • Pitfalls of pharmacoepidemiology.
    Farmer R, Williams T, Nightingale A. Farmer R, et al. BMJ. 2000 Nov 25;321(7272):1352. doi: 10.1136/bmj.321.7272.1352. BMJ. 2000. PMID: 11186450 Free PMC article. No abstract available.

References

    1. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582–1588. - PubMed
    1. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593. - PubMed
    1. Bleomenkamp KWM, Rosendaal FR, Helmerhorts FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet. 1995;346:1593–1596. - PubMed
    1. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Baech J, et al. Third-generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost. 1998;79:23–31. - PubMed
    1. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354:127–128. - PubMed